Research To Practice | Oncology Videos

View Top 200 Chart

Back to Rankings Page

Science
**Research To Practice | Oncology Videos**

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

Latest Episodes:

Multiple Myeloma — Optimizing the Selection of First-Line Therapy with Dr Saad Zafar Usmani Feb 06, 2025

Show notes

Featuring an interview with Dr Saad Zafar Usmani, including the following topics:

Optimizing treatment intervention for patients with newly diagnosed multiple myeloma (MM) (0:00)
Role of anti-CD38 antibodies in induction and maintenance therapy for patients with newly diagnosed disease (4:22)
Case: A woman in her late 70s with revised International Staging System (R-ISS) Stage II IgG kappa myeloma who received D-Rd followed by maintenance daratumumab (14:02)
Case: A man in his early 60s with double-hit myeloma who received D-KRd and carfilzomib maintenance therapy (26:10)
Case: A man in his early 70s with R-ISS Stage III IgG kappa myeloma and translocation (4;14) who deferred transplant (33:24)
Future directions in the management of MM (40:37)

CME information and select publications

Multiple Myeloma — Optimizing the Selection of First-Line Therapy with Dr Saad Zafar Usmani (Companion Faculty Lecture) Feb 04, 2025

Show notes

Featuring a slide presentation and related discussion from Dr Saad Zafar Usmani, including the following topics:

Evolution of therapeutic decision-making for patients with newly diagnosed multiple myeloma (MM) (0:00)
Quadruplet therapy for transplant-eligible patients with newly diagnosed MM (6:26)
Daratumumab with lenalidomide as maintenance therapy after transplant in newly diagnosed MM (16:16)
Therapeutic options for transplant-ineligible patients with MM (19:51)

CME information and select publications

5-Minute Journal Club Issue 3 with Dr Seth Wander: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer Jan 31, 2025

Show notes

Featuring an interview with Dr Seth Wander, including the following topics:

The clinical utility of ESR1 mutations in HR-positive, HER2-negative advanced breast cancer
- Grinshpun A et al. The clinical utility of ESR1 mutations in hormone receptor-positive, HER2-negative advanced breast cancer. Hematol Oncol Clin North Am 2023;37(1):169-81. Abstract (0:00)
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and in combination with targeted therapy for ER-positive, HER2-negative advanced breast cancer
- Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and in combination with targeted therapy in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Phase Ia/Ib EMBER study. J Clin Oncol 2024;[Online ahead of print]. Abstract (6:01)
EORTC-2129-BCG: Elacestrant for ER-positive/HER2-negative breast cancer patients with ctDNA relapse
- Ignatiadis M et al. EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA). ESMO 2024;Abstract 338TiP. (8:20)

CME information and select publications

Chronic Lymphocytic Leukemia with Dr Jennifer Woyach: Part 3 of a 3-Part Meet The Professor Series Jan 30, 2025

Show notes

Featuring perspectives from Dr Jennifer Woyach, including the following topics:

AMPLIFY — First-Line Trials Combining Bruton Tyrosine Kinase (BTK) Inhibitors with Venetoclax
- Introduction (0:00)
- Case: An African American man in his mid 40s with progressive lymphadenopathy in the neck is diagnosed with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with trisomy 12 and an SF3B1 mutation — Erik Rupard, MD (1:50)
Pirtobrutinib
- Questions for the Faculty: Effectiveness and tolerability of pirtobrutinib for patients with CLL and disease progression on prior BTK inhibition — Zanetta S Lamar, MD (21:18)
Choice of First-Line BTK Inhibitor
- Case: A woman in her mid 80s diagnosed with CLL more than 30 years ago now has relapsed/refractory, ibrutinib-intolerant disease — Warren S Brenner, MD (31:29)
Cardiotoxicity of BTK Inhibitors
- Case: A man in his early 70s with chronic atrial fibrillation requiring long-term anticoagulation is diagnosed with IGHV-unmutated CLL with del(13q), del(17p) and an XPO1 mutation — Bhavana (Tina) Bhatnagar, DO (34:53)
- Case: A man in his mid 70s with trisomy 12, IGHV-unmutated CLL has a history of congestive heart failure (ejection fraction 20% to 25%) resulting in multiple hospital admissions — Laurie Matt-Amaral, MD, MPH (37:51)
CLL and COVID-19 Vaccinations; Role of MRD Testing; Anti-CD20 Antibodies
- Case: A man in his early 60s with CLL receives first-line obinutuzumab/venetoclax and has a moderate infusion reaction to obinutuzumab — Dr Rupard (41:17)
- Case: A man in his early 60s with CLL and well controlled autoimmune hemolytic anemia on ibrutinib is switched to zanubrutinib — Dr Lamar (45:26)
- Questions for the Faculty: CLL and COVID-19 vaccinations; role of MRD testing; anti-CD20 antibodies — Dr Brenner (49:23)
- Case: An Amish man in his mid 60s requires treatment for CLL but is paying for treatment "out of pocket" — Dr Rupard (55:33)

CME information and select publications

Metastatic Triple-Negative Breast Cancer — Oncology Q&A for Clinicians: Discussing Common Questions Posed by Patients Jan 24, 2025

Show notes

Featuring perspectives from Dr Lisa Carey and Dr Rita Nanda, including the following topics:

Introduction (0:00)
Patient Videos and Clinical Investigator Survey (3:26)
San Antonio Breast Cancer Symposium (SABCS®) Report — Education Session on Antibody-Drug Conjugates (26:03)
Patient Videos and Clinical Investigator Survey (43:27)
SABCS Report — Abstracts of Interest (55:56)
Patient Videos and Clinical Investigator Survey (56:27)

CME information and select publications

Metastatic Triple-Negative Breast Cancer | Oncology Q&A for Patients with Metastatic Triple-Negative Breast Cancer Jan 17, 2025

Show notes

Featuring perspectives from Dr Lisa A Carey and Dr Rita Nanda, including the following topics:

Introduction (0:00)
Stages of Triple-Negative Breast Cancer (TNBC); Recurrence After Adjuvant Treatment (5:28)
Long-Term Outcomes with Metastatic TNBC (11:55)
Side Effects and Complications of Treatment (24:42)
Dose Reduction (30:27)
Working While Receiving Treatment (32:24)
Support for Minor Children and Grandchildren (37:12)
Second Opinions and Self Advocacy (42:53)
Recording Clinic Visits; Complementary Therapies; Nutrition (48:38)
Living Wills and Advanced Directives (55:41)

Please take our survey

Lymphoma | What Clinicians Want to Know: Addressing Current Questions and Controversies Regarding the Role of CAR T-Cell Therapy and Bispecific Antibodies in the Management of Lymphoma Jan 16, 2025

Show notes

Featuring perspectives from Dr Jeremy S Abramson, Dr Jennifer Crombie, Prof Martin Hutchings, Dr Matthew Lunning and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics:

Introduction (0:00)
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Abramson (2:17)
Bispecific Antibody Therapy for DLBCL — Prof Hutchings (28:51)
CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Lunning (52:01)
Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:17:46)
Tolerability Considerations with CAR T-Cell and Bispecific Antibody Therapy — Dr Crombie (1:41:44)

CME information and select publications

Myelofibrosis | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Myelofibrosis Jan 14, 2025

Show notes

Featuring perspectives from Dr Alexander Perl, Dr Eytan M Stein, Dr Richard M Stone, Dr Eunice S Wang and Prof Andrew H Wei, moderated by Dr Stein, including the following topics:

Introduction (0:00)
Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias — Dr Kuykendall (2:53)
Managing MF for Patients with Thrombocytopenia — Dr Bose (32:45)
Managing MF for Patients with Anemia — Dr Yacoub (59:47)
Future Directions in the Management of MF — Dr Fleischman (1:27:53)

CME information and select publications

Metastatic Breast Cancer | Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of Metastatic Breast Cancer Jan 10, 2025

Show notes

Featuring perspectives from Dr Erika Hamilton, Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O'Shaughnessy and Dr Sara M Tolaney, including the following topics:

Introduction (0:00)
Optimizing the Care of Patients with HER2-Positive Metastatic Breast Cancer (mBC) — Dr Krop (10:17)
Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Dr Tolaney (37:54)
Integrating Novel Agents and Approaches into the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Kalinsky (53:59)
Tolerability Considerations with Approved and Investigational Antibody-Drug Conjugates — Dr O'Shaughnessy (1:14:16)
Other Important Care Considerations for Patients with mBC — Dr Hamilton (1:41:30)

CME information and select publications

Chronic Myeloid Leukemia | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Chronic Myeloid Leukemia Jan 09, 2025

Show notes

Featuring perspectives from Prof Andreas Hochhaus, Dr Michael J Mauro and Dr B Douglas Smith, moderated by Dr Mauro, including the following topics:

Introduction (0:00)
Up-Front Therapy for Chronic Myeloid Leukemia (CML) — Prof Hochhaus (2:45)
Management of Relapsed CML, Including in Patients with a T315I Mutation — Dr Mauro (29:23)
Tolerability and Other Practical Issues with Commonly Employed CML Therapies — Dr Smith (1:00:15)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected